Revision history
Back to the articleThese are preserved drafts. Earlier evidence may have changed; use the current reading to check availability.
Revision 1 · Immunotherapy improved allergic asthma but increased systemic reactions
Saved 2026-09-15 · Not clinically reviewed
Read this saved revision and its sources
A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm. Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms.
A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm.
What the study found
A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm.
Immunotherapy improved asthma symptoms, medication scores and FEV1, but it also increased systemic reactions.
Who and what was studied
The included randomized trials involved people with allergic asthma and were analyzed by age and allergen type.
The review compared subcutaneous and sublingual immunotherapy, reporting greater efficacy with the subcutaneous route.
What remains uncertain
Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms.
Which parts of this research are relevant to the questions I should discuss with my care team?